GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMA) » Definitions » EPS without NRI

Dermata Therapeutics (Dermata Therapeutics) EPS without NRI : $-32.74 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics EPS without NRI?

Dermata Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-7.05. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-32.74.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 25.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Dermata Therapeutics's EPS without NRI or its related term are showing as below:

DRMA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -15.3   Med: 5.15   Max: 25.6
Current: 25.6

During the past 5 years, Dermata Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 25.60% per year. The lowest was -15.30% per year. And the median was 5.15% per year.

DRMA's 3-Year EPS without NRI Growth Rate is ranked better than
75.1% of 1297 companies
in the Biotechnology industry
Industry Median: 5.5 vs DRMA: 25.60

Dermata Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-7.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-32.74.

Dermata Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-7.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-32.74.


Dermata Therapeutics EPS without NRI Historical Data

The historical data trend for Dermata Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermata Therapeutics EPS without NRI Chart

Dermata Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
-136.05 -97.12 -583.20 -208.80 -40.05

Dermata Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.05 -9.45 -8.10 -8.14 -7.05

Competitive Comparison of Dermata Therapeutics's EPS without NRI

For the Biotechnology subindustry, Dermata Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermata Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Dermata Therapeutics's PE Ratio without NRI falls into.



Dermata Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermata Therapeutics  (NAS:DRMA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Dermata Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermata Therapeutics (Dermata Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
Executives
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Gerald T Proehl 10 percent owner, officer: Pres., CEO and Chairman
Van Hoose Kyri K. officer: Chief Financial Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
David F Hale director 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Wendell Wierenga director C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555
Kathleen D. Scott director C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Thomas Insley officer: Chief Financial Officer SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010
Bedoya-toro Munera Maria E officer: Senior VP 10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130
Andrew Seth Sandler director 1301 2ND AVE, SEATTLE WA 98101
Christopher J. Nardo officer: Senior VP, Development C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Proehl Investment Ventures Llc 10 percent owner C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130

Dermata Therapeutics (Dermata Therapeutics) Headlines